Advertisement

Topics

ICER updates value-based price benchmark for PCSK9 inhibitor Praluent

10:13 EDT 14 Mar 2018 | thePharmaLetter

The Institute for Clinical and Economic Review (ICER) has released a Preliminary New Evidence Update…

Original Article: ICER updates value-based price benchmark for PCSK9 inhibitor Praluent

NEXT ARTICLE

More From BioPortfolio on "ICER updates value-based price benchmark for PCSK9 inhibitor Praluent"

Advertisement
Quick Search
Advertisement
Advertisement